Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of utidelone + platinum chemotherapy + envafolimab in advanced non-small cell lung cancer
ChiCTR2300067590Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Sep 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of utidelone, cisplatin, carboplatin and envafolimab in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Overall objective response rate. Started Sep 2022; status: recruiting.
02
Drugs
utidelonecisplatincarboplatinenvafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300067590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067590.